戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 evacizumab, atezolizumab alone or sorafenib (multikinase inhibitor).
2 nter trials evaluating last-line treatments (multikinase inhibitors).
3 ive iodine who had never been treated with a multikinase inhibitor.
4 ors were also resistant to a VEGFR targeting multikinase inhibitor.
5  from the toxicity profiles of the available multikinase inhibitors.
6 peutic strategy of improving the efficacy of multikinase inhibitors.
7 drives resistance of glioma cells to various multikinase inhibitors.
8 ctivity associated with several FDA-approved multikinase inhibitors.
9                                              Multikinase inhibitor and immune checkpoint blockade com
10                               Sorafenib is a multikinase inhibitor and the only FDA-approved treatmen
11 pindle cell sarcoma who did not respond to a multikinase inhibitor and therefore had limited treatmen
12 enib, and regorafenib and resistant to other multikinase inhibitors and chemotherapeutic drugs.
13                               Antiangiogenic multikinase inhibitors and targeted therapies to genetic
14                                 Sorafenib, a multikinase inhibitor approved for the treatment of adva
15                                 Sorafenib, a multikinase inhibitor approved for the treatment of RCC,
16 otocols to monitor responses to sorafenib, a multikinase inhibitor approved for treatment of renal ce
17                            Cabozantinib is a multikinase inhibitor approved in multiple malignancies.
18                                              Multikinase inhibitors are effective treatments for thyr
19                The discovery of sorafenib, a multikinase inhibitor, as a treatment with survival bene
20 sses the outcomes of acitretin treatment for multikinase inhibitor-associated hand-foot skin reaction
21  addition, the combination of IACS-10759 and multikinase inhibitor cabozantinib had improved antitumo
22  or had been treated previously with a VEGFR multikinase inhibitor (cohort 2).
23 rum of FDA-approved drugs, we found that the multikinase inhibitor dasatinib potently inhibited the g
24 rug-regulatable system or treatment with the multikinase inhibitor dasatinib resulted in the acquisit
25        These mutations were sensitive to the multikinase inhibitor dasatinib, which antagonizes TNK2
26  hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and ot
27                               Antiangiogenic multikinase inhibitors (eg, sorafenib, lenvatinib, caboz
28 rface and sorafenib, a potent antineoplastic multikinase inhibitor, encapsulated in the core.
29 oparticle containing cabozantinib (XL184)--a multikinase inhibitor--encapsulated inside.
30                           Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in
31                            Since then, other multikinase inhibitors have been approved.
32 hese cancers, although only early-generation multikinase inhibitors have been granted regulatory appr
33                                              Multikinase inhibitors have shown potential in treating
34 inhibitors (HR = 0.60; 95% CI 0.46-0.79) and multikinase inhibitors (HR = 0.49; 95% CI 0.27-0.89) wer
35 s in vitro against several promising anti-NB multikinase inhibitors: imatinib, dasatinib, crizotinib,
36 y confirmed response reported to date with a multikinase inhibitor in advanced GEP-NETs, with a parti
37 e of the proteome to the drug Regorafenib, a multikinase inhibitor, in HCT 116 spheroids.
38                         Indeed, sorafenib (a multikinase inhibitor) is currently being used in the su
39                                          The multikinase inhibitor lestaurtinib inhibited PKN1 action
40 previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3
41 xis in normoxia and hypoxia and suggest that multikinase inhibitors may exert antiangiogenic effects
42     Our aim was to ascertain if sorafenib, a multikinase inhibitor, may also inhibit JAK/STAT signali
43                                          The multikinase inhibitor META060 has been shown to inhibit
44                                          The multikinase inhibitor midostaurin inhibits KIT D816V, a
45  patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved
46                                   The use of multikinase inhibitors (MKI) in oncology, such as sorafe
47 lorectal cancer (mCRC) patients treated with multikinase inhibitors (MKI).
48                                              Multikinase inhibitors (MKIs) showing anti-RET activitie
49 -altered cancers were initially treated with multikinase inhibitors (MKIs).
50                    GSK1363089 (foretinib), a multikinase inhibitor of AXL, MET, and vascular endothel
51                                 Sorafenib, a multikinase inhibitor of cell proliferation and angiogen
52                            Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which
53                              Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and
54 a result of the nonselective nature of these multikinase inhibitors, patients had off-target adverse
55              In this study, we show that the multikinase inhibitor PKC412, which is currently in clin
56                            The Kit-targeting multikinase inhibitors PKC412 and dasatinib were also fo
57                                              Multikinase inhibitors (ponatinib, sunitinib, sorafenib)
58 tudy assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal
59  SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma su
60 ational phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients.
61 down of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduced.
62 ition is a novel mechanistic explanation for multikinase inhibitor resistance in glioma cells.
63                           The effects of the multikinase inhibitor sorafenib (BAY 43-9006), an agent
64                                          The multikinase inhibitor sorafenib (Nexavar, Bayer), used i
65 ve drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib (SFB) usually fails to e
66      We examined the interaction between the multikinase inhibitor sorafenib and histone deacetylase
67                      We examined whether the multikinase inhibitor sorafenib and histone deacetylase
68                     Interactions between the multikinase inhibitor sorafenib and the BH3-mimetic obat
69                     Interactions between the multikinase inhibitor sorafenib and tumor necrosis facto
70 te stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in pat
71          We previously demonstrated that the multikinase inhibitor sorafenib induces apoptosis in mel
72                                     Only the multikinase inhibitor sorafenib is available for the man
73 advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic tre
74                             In addition, the multikinase inhibitor sorafenib significantly reduces FB
75                                          The multikinase inhibitor sorafenib yielded similar effects
76 r rapamycin alone or in combination with the multikinase inhibitor sorafenib, all xenografts responde
77 antly, we found that the clinically valuable multikinase inhibitor sorafenib, and a natural alkaloid,
78 he molecular mechanism of the oral antitumor multikinase inhibitor sorafenib, we profiled the express
79 the kinase most efficiently inhibited by the multikinase inhibitor sorafenib, which has shown activit
80 patient before and during treatment with the multikinase inhibitor sorafenib.
81 zed with diverse drug classes, including the multikinase inhibitor sorafenib.
82 on increased the therapeutic efficacy of the multikinase inhibitor sorafenib.
83 ma (CRC) metastatic to the liver include the multikinase inhibitors sorafenib and regorafenib.
84 ies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated
85                                   Recently a multikinase inhibitor, sorafenib, has shown survival ben
86 rapy against mCRPC-infiltrating MDSCs, using multikinase inhibitors such as cabozantinib and BEZ235,
87 h sunitinib (Sutent), an additional approved multikinase inhibitor, suggesting that the primary targe
88                                          The multikinase inhibitors sunitinib, sorafenib, and axitini
89                                 Sorafenib, a multikinase inhibitor targeting cell growth and angiogen
90                      Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR
91 he safety and efficacy of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, an
92                         Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and
93                                 Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed an
94  effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculatur
95     Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had
96    Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial gr
97          Several new targeted therapies with multikinase inhibitors targeting vascular endothelial gr
98 n U.S. Food and Drug Administration-approved multikinase inhibitor that also targets Src family, dram
99                               Sorafenib is a multikinase inhibitor that induces apoptosis in human le
100  that mutp53 increases sensitivity to SOR, a multikinase inhibitor that induces endoplasmic reticulum
101      Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating
102  previously unknown drug-like small molecule multikinase inhibitor that regulates splicing of Syngap1
103 sistance could be overcome with ponatinib, a multikinase inhibitor that targets BCR-ABL and FGF recep
104    This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and recept
105                               BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor c
106                         Sorafenib is an oral multikinase inhibitor that targets the Ras/Raf/MEK/ERK m
107 neoplastic drug sorafenib (BAY 43-9006) is a multikinase inhibitor that targets the serine-threonine
108                         Sorafenib is an oral multikinase inhibitor that was originally developed as a
109                        Sorafenib is an oral, multikinase inhibitor that was recently approved for use
110              Despite the approval of several multikinase inhibitors that target SRC and the overwhelm
111 ere sensitive to treatment with sorafenib, a multikinase inhibitor, that is used for HCC treatment.
112 geting nanoparticles (NPs) with sorafenib, a multikinase inhibitor, the NPs could suppress collagen s
113                                 Dasatinib, a multikinase inhibitor, was effective against 50% of DLBC
114        Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase a
115                            Cabozantinib is a multikinase inhibitor with activity against RET that pro
116                           Pazopanib, an oral multikinase inhibitor with activity against vascular end
117                               Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferat
118                     Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activit
119                              Crizotinib is a multikinase inhibitor with potent activity against MET(3
120 vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity ag
121 ffects of merestinib, an orally bioavailable multikinase inhibitor with suppressive effects on Mnk ac
122      Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat
123 ION: Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat
124 olypharmacological approaches for developing multikinase inhibitors with low toxicity profiles.
125                                              Multikinase inhibitors with RET inhibitor activity, such
126 hase I trial combining dasatinib, an SFK and multikinase inhibitor, with erlotinib, an EGFR inhibitor
127 FR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity again

 
Page Top